한글목차

메토니다졸은 경증에서 중등도 클로스트리듐 디피실 감염증(CDI)의 초기 치료의 주축을 이루었습니다. 최근까지 메트로니다졸은 경증에서 중등도의 CDI 초기 사례에 대해 반코마이신보다 메트로니다졸을 1차 선택 약물로 권장했습니다.

경증 CDI 환자에서 반코마이신과 메트로니다졸은 사망률, CDI 재발 및 임상적 치유에 있으며, 차이가 없습니다는 것이 여러 연구에서 입증되었습니다. 메트로니다졸은 반코마이신에 비해 가격이 저렴하고, 집락 형성 및 내성균 발생이 적을 수 있습니다.

앞으로 수년간 클로스트리듐 디피실 감염증 시장 시나리오는 세계에서 광범위한 조사와 의료비 지출 증가로 인해 변화할 것입니다. 각 업체들은 질병을 치료/개선하기 위한 새로운 접근 방식에 초점을 맞춘 치료법을 개발하고 과제를 평가하며 메트로니다졸의 우위에 영향을 미칠 수 있는 기회를 모색하고 있습니다. 클로스트리듐 디피실 감염에 대한 다른 신흥 제품들은 메트로니다졸과 치열한 시장 경쟁을 벌일 것으로 예상되며, 가까운 시일 내에 후발주자 신약이 출시될 경우 시장에 큰 영향을 미칠 것으로 보입니다.

주요 7개국의 메트로니다졸 시장에 대해 조사했으며, 시장의 개요와 2023-2032년 판매 예측 데이터, 경쟁 구도 및 국가별 동향 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 클로스트리듐 디피실 감염증에 대한 메트로니다졸의 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 규제상 마일스톤
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신규 치료법)

제5장 메트로니다졸 시장 평가

• 클로스트리듐 디피실 감염증에 대한 메트로니다졸의 시장 전망
• 주요 7개국 시장 분석
  • 클로스트리듐 디피실 감염증에 대한 메트로니다졸의 주요 7개국의 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

“"Metronidazole Drug Insight and Market Forecast - 2032" report provides comprehensive insights about metronidazole for clostridium difficile infection (CDI) in the seven major markets. A detailed picture of the metronidazole for clostridium difficile infection in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the metronidazole for clostridium difficile infection. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the metronidazole market forecast analysis for clostridium difficile infection in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in clostridium difficile infection.

Drug Summary:

Metronidazole has been the mainstay of treatment for initial cases of mild to moderate clostridium difficile infection (CDI). Until recently, metronidazole was recommended as the first-line treatment option over vancomycin for initial cases of mild to moderate CDI.

Among patients with mild CDI, several studies have demonstrated no difference between vancomycin and metronidazole for mortality, CDI recurrence, or clinical cure. Metronidazole is less expensive and may be associated with lower colonization and/or development of drug-resistant organisms compared with vancomycin.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the metronidazole description, mechanism of action, dosage and administration, research and development activities in clostridium difficile infection.
• Elaborated details on metronidazole regulatory milestones and other development activities have been provided in this report.
• The report also highlights the metronidazole research and development activities in clostridium difficile infection across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around metronidazole.
• The report contains forecasted sales of metronidazole for clostridium difficile infection till 2032.
• Comprehensive coverage of the late-stage emerging therapies for clostridium difficile infection.
• The report also features the SWOT analysis with analyst views for metronidazole in clostridium difficile infection.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Metronidazole Analytical Perspective by DelveInsight

In-depth Metronidazole Market Assessment

This report provides a detailed market assessment of metronidazole for clostridium difficile infection in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

Metronidazole Clinical Assessment

The report provides the clinical trials information of metronidazole for clostridium difficile infection covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for clostridium difficile infection is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence metronidazole dominance.
• Other emerging products for clostridium difficile infection are expected to give tough market competition to metronidazole and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of metronidazole in clostridium difficile infection.
• Our in-depth analysis of the forecasted sales data of metronidazole from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the metronidazole in clostridium difficile infection.

Key Questions:

• What is the product type, route of administration and mechanism of action of metronidazole?
• What is the clinical trial status of the study related to metronidazole in clostridium difficile infection and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the metronidazole development?
• What are the key designations that have been granted to metronidazole for clostridium difficile infection?
• What is the forecasted market scenario of metronidazole for clostridium difficile infection?
• What are the forecasted sales of metronidazole in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to metronidazole for clostridium difficile infection?
• Which are the late-stage emerging therapies under development for the treatment of clostridium difficile infection?

Table of Contents

1. Report Introduction

2. Metronidazole Overview in Clostridium difficile infection

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Metronidazole Market Assessment

• 5.1. Market Outlook of Metronidazole in Clostridium difficile infection
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Metronidazole in the 7MM for Clostridium difficile infection
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Metronidazole in the United States for Clostridium difficile infection
  • 5.3.2. Market Size of Metronidazole in Germany for Clostridium difficile infection
  • 5.3.3. Market Size of Metronidazole in France for Clostridium difficile infection
  • 5.3.4. Market Size of Metronidazole in Italy for Clostridium difficile infection
  • 5.3.5. Market Size of Metronidazole in Spain for Clostridium difficile infection
  • 5.3.6. Market Size of Metronidazole in the United Kingdom for Clostridium difficile infection
  • 5.3.7. Market Size of Metronidazole in Japan for Clostridium difficile infection

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options